Quantcast

Latest Morpholines Stories

2014-09-04 23:01:58

The results of a recently-concluded study purport to show that Xarelto (rivaroxaban) is as safe as warfarin for patients atrial fibrillation patients awaiting elective cardioversion, even though four persons included in the study died. Rockville Centre, NY (PRWEB) September 04, 2014 According to an article published on September 2 at medpagetoday.com, atrial fibrillation patients awaiting elective cardioversion who had their oral anticoagulant switched from warfarin to Xarelto “were...

2014-09-02 04:21:13

X-VeRT Study Results Presented as a Hot Line Session at the ESC Congress 2014 and Published in European Heart Journal BARCELONA, Spain, Sept. 2, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) and its development partner, Bayer HealthCare, announced today results from the X-VeRT trial, demonstrating once-daily XARELTO(®) (rivaroxaban) may be an alternative to vitamin K antagonists (VKA) in treating and reducing the risk of blood clots in non-valvular atrial...

2014-08-27 08:27:31

SAN DIEGO, Aug. 27, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Baird 2014 Health Care Conference to be held at The New York Palace Hotel in New York City on September 3-4, 2014. Alan Fuhrman, Ambit's CFO, will provide an overview of the Company and its lead drug candidate,...

2014-08-25 08:27:37

-- Results from X-VeRT, the first prospective exploratory study of a Factor Xa inhibitor in patients with atrial fibrillation undergoing cardioversion, will be presented during an ESC Congress 2014 Hot Line Session RARITAN, N.J., Aug. 25, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that results from the Phase 3b exploratory X-VeRT study, investigating the oral Factor Xa inhibitor XARELTO(®) (rivaroxaban) in patients with non-valvular atrial...

2014-08-12 23:10:53

The DrugNews Center is the web’s largest source for prescription drug warnings, research and legal news. Visit http://www.DrugNews.net today. New York, NY (PRWEB) August 12, 2014 The drug safety advocates at DrugNews.net have added a new resource section for patients who have taken the anticoagulant drug Xarelto. Recent reports show internal bleeding complaints for the drug have risen past similar medications*. DrugNews is a free resource providing the latest product recalls, safety...

2014-08-12 08:29:26

Array planning for potential return of MEK inhibitor BOULDER, Colo., Aug. 12, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the fourth quarter and full year of its fiscal year ending June 30, 2014. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO Ron Squarer, Chief Executive Officer of Array, noted, "The Array-invented MEK inhibitors, binimetinib and selumetinib, are currently enrolling six Phase 3 trials, and each of our partners has...

2014-08-09 23:03:28

Court Documents Indicate a Number of Xarelto Bleeding Lawsuits Have Been Filed In U.S. Courts on Behalf of Individuals Who Allegedly Suffered Life-Threatening Internal Hemorrhage Due to Their Use of the Blood Thinner Columbus, OH (PRWEB) August 09, 2014 Wright & Schulte LLC has launched a new Xarelto lawsuit page in response to the growing litigation involving the blood thinner. According to a Reuters report published June 14, 2014, Bayer AG and Janssen Pharmaceuticals are named as...

2014-08-04 08:27:13

Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 4, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its...

2014-07-29 08:31:52

SAN DIEGO, July 29, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced it will report second quarter operational results after closing of the NASDAQ Global Market on Tuesday, August 12, 2014. A conference call hosted by Michael Martino, president and CEO, and other members of senior management will take place on the...

2014-07-28 04:21:34

HILDEN, Germany and LONDON, July 28, 2014 /PRNewswire/ -- - Collaboration aims to create and commercialize companion diagnostic using genomic data from plasma samples to guide the use of IRESSA for non-small cell lung cancer patients - New blood test will build on QIAGEN's FDA-approved therascreen EGFR test and is planned to run on Rotor-Gene Q, member of the QIAsymphony family of automated instruments -...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'